arrow
L

Lingzhi Hong

md anderson cancer center
H指数:23
被引数:2,619

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study

PP01.48: 化疗放疗联合Durvalumab巩固治疗后不可切除III期NSCLC进展后的治疗策略与免疫疗法再挑战敏感性:POST-PACIFIC研究

2026-07-030
PRE
Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study

深度学习CT成像预测转移性NSCLC中PD-L1表达和免疫治疗效果:一项多中心研究

2026-06-190
PRE
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors

复合EGFR突变主要是PACC(P环和α-C螺旋压缩)突变,对第二代与第三代酪氨酸激酶抑制剂的敏感性增加

2026-05-260
PRE
Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer

开发PET/CT-临床列线图以预测原发性肺癌淋巴结转移

2025-12-170
OAAI
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients

基于放射组学的动态肺癌风险预测(针对USPSTF非适用人群)

2025-10-230
OAAI
CoCo-ST detects global and local biological structures in spatial transcriptomics datasets

Coco-st检测空间转录组数据集中的全局和局部生物结构

2025-10-130
OA
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

poziotinib 用于 EGFR 外显子 20 插入型 NSCLC:ZENITH II 期试验的临床疗效及 EGFR 外显子 20 插入位点对敏感性的差异化影响

2025-09-240
OAAI
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study

肺肉瘤样癌的特定临床基因组学特征及与免疫治疗的相关性:一项多中心回顾性研究

2025-07-250
OAAI
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

机器学习驱动的转移性非小细胞肺癌免疫治疗适应性策略

2025-07-240
OAAI
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception

人类和小鼠肺腺癌前体物的空间与多组学分析揭示TIM-3可作为癌症拦截的潜在靶点

2025-05-080
OA
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model

利用Brock模型和Sybil模型对持续性肺结节患者进行肺癌风险评估

CANCERS
IF4.4
2025-04-290
OA
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

黏液性组织学特征的肺腺癌:临床、基因组学和免疫微环境特征及对基于免疫疗法治疗和KRASG12C抑制剂的疗效

2025-03-014
PRE
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors
2025-01-010
PRE
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

通过PET/CT栖息地成像,ctDNA和综合放射基因组学增强NSCLC复发预测-血液见解

2024-04-115
OAAI
Spatial single-cell immune microenvironment analysis reveals the transition from innate to adaptive immune response during early lung adenocarcinoma carcinogenesis
2024-03-220
PRE
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

CT合成PET改善肺癌的诊断和预后: 概念验证

2024-03-013
OAAI
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
2023-12-019
OAAI